Psychedelics.

Start with the compound

Classic psychedelics such as psilocybin, LSD, DMT and mescaline share some activity in the serotonin system, but they are different substances. MDMA, ketamine and ibogaine are often discussed alongside them and have different actions and risks. A result for one compound, product, condition or supervised setting does not automatically apply to the rest.

Explore MDMA-assisted therapy and PTSD, microdosing and the evidence, and DMT and depression.12

Mechanism is a question, not an outcome

The body converts psilocybin to psilocin. Classic psychedelics share some activity at a receptor called 5-HT2A. Researchers can study how a substance affects receptors and brain signalling, but that does not by itself establish a lasting treatment benefit. Changes in brain activity or the intensity of an experience are different from changes in symptoms, daily function and harms.12

The treatment studied is usually a package

Many trials study a substance together with preparation, supervision, monitoring and psychological support. That is not the same as unsupervised use. Trials also differ in who takes part, the diagnosis, therapist training, what is measured, the comparison treatment and the length of follow-up. These details determine what the results can answer.2

What the clinical evidence can and cannot say

Psilocybin research has examined depression, anxiety associated with serious illness and alcohol use disorder, among other questions. Some randomised studies report symptom differences over short follow-up periods; interpretation still depends on the selected population, comparator, psychotherapy context, adverse events, missing data and durability. A 2022 treatment-resistant-depression trial reported a between-group symptom difference at three weeks. A separate 2022 major-depressive-disorder trial reported lower symptom scores 14 days after treatment than placebo and called for larger multicentre studies with longer follow-up. A 2023 11-site US trial extended the evidence to day 43 in general MDD, but was Usona-sponsored, used niacin as comparator and enrolled a selected sample in which only 12.5% met the study's TRD definition. The 2026 two-centre German EPIsoDE trial in treatment-resistant depression did not meet its primary six-week response endpoint versus nicotinamide, although exploratory secondary symptom-score results favored the 25-mg group. Two serious adverse reactions followed 25 mg, including one case of hallucinogen persisting perception disorder. Other small single-site randomized and feasibility trials reported in 2026 add follow-up and service-delivery questions, not approval or head-to-head evidence. These are study findings, not universal treatment recommendations.457891011

A different compound, a different question: MDMA and PTSD

MDMA is often grouped with psychedelics in treatment research, but it is not a classic psychedelic and findings cannot be transferred to psilocybin. In a 2023 phase 3 trial, adults with moderate-to-severe post-traumatic stress disorder received either MDMA with a structured therapy programme or placebo with the same therapy. At the study endpoint, 37 of 52 assessed in the MDMA group and 20 of 42 in the placebo group no longer met diagnostic criteria; that diagnostic measure was not the primary symptom-scale outcome. Severe treatment-emergent events were reported in five participants in the MDMA group and two in the placebo group (the safety denominator was larger than the diagnostic-outcome denominator). The study was funded by MAPS, with the associated public-benefit company overseeing data collection and analysis. The noticeable effects of MDMA can compromise masking, and the selected population, structured support and limited follow-up affect generalisability. In June 2024, an FDA advisory committee recorded concerns about functional unblinding and expectation bias, voted 2 yes to 9 no on whether the available data showed effectiveness and 1 yes to 10 no on whether benefits outweighed risks with the proposed risk-management plan; those were advisory votes, not an FDA approval or final regulatory determination. A trial result is not a regulatory approval.12213

Safety belongs in the headline

Short-term experiences can include fear, confusion, panic, nausea, increased heart rate or blood pressure, and impaired judgement. Risk depends on the substance, amount, setting, other substances and the person’s health. Some trials exclude people with psychotic disorders or severe bipolar presentations because their risks and benefits may differ.

For psilocybin, case reports and reviews describe persistent perceptual symptoms, but their frequency and causal relationship are not established. Other longer-term questions include mood or psychosis-related events, repeated use, interactions and possible heart effects for compounds with relevant receptor activity. A small, screened trial cannot establish safety for everyone.123

Approval, access and legality are separate

A research study, a breakthrough-therapy designation, a local policy and marketing authorisation are different things. FDA guidance supports clinical development; it does not approve psilocybin, LSD or another psychedelic for general treatment. Rules for possession, supervised services, research access and prescribing vary by place and can change. This site is not a country-by-country legal guide.26

A reader's check

Which compound and product were studied, and in what setting? Who was included or excluded? What was the comparison, and could people tell which treatment they received? What changed, by how much and for how long? What harms, expectations, missing data and later evidence could change the conclusion? These details keep a result about one study from becoming a claim about an entire category.